Expanding Horizons: Pioneering Healthcare Innovation

From humble beginnings as a contract manufacturer for industry leaders, this company has come a long way. Now, the company is strategically transitioning from a B2B model to a B2B2C approach, offering a diverse array of healthcare solutions. They are focusing on branded segments like Petcare, Nutrition, and Cosmetics. They have set ambitious targets, aiming for a robust 25-30% CAGR growth between FY24 to FY26, while maintaining a healthy EBITDA margin of 12-15%. Currently trading at a multiple of 25x FY24 earnings, the stock presents an enticing opportunity, considering its strong growth prospects.

Simplifying The Pharma Value Chain

The pharma value chain refers to the series of activities involved in the creation, production, distribution, and delivery of pharma products to consumers.
In this article, we shall exclusively address the constituents integral to drug formulation.